530
Participants
Start Date
June 6, 2019
Primary Completion Date
May 27, 2023
Study Completion Date
August 9, 2023
andexanet alfa
Andexanet alfa is a recombinant version of human FXa
Usual Care
Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
Research Site, Rome
Research Site, Rome
Research Site, Oslo
Research Site, Vienna
Research Site, Dresden
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Belgium
Research Site, Dresden
Research Site, Ottignies
Research Site, Copenhagen Ø
Research Site, Leuven
Research Site, Bern
Research Site, Sankt Pölten
Research Site, Genk
Research Site, Linz
Research Site, Debrecen
Research Site, Vilnius
Research Site, Altenburg
Research Site, Odense C
Research Site, Salzburg
Research Site, Innsbruck
Research Site, Pécs
Research Site, Århus N
Research Site, Kortrijk
Research Site, Ghent
Research Site, Klagenfurt
Research Site, Aalborg
Research Site, Chemnitz
Research Site, Albany
Research Site, Athens
Research Site, Genova
Research Site, Allentown
Research Site, Milan
Research Site, Hamburg
Research Site, Hamburg
Research Site, Lübeck
Research Site, Lleida
Research Site, Sande
Research Site, Madrid
Research Site, Madrid
Research Site, Bremen
Research Site, Hanover
Research Site, Augusta
Research Site, Toulouse
Research Site, Bordeaux
Research Site, Fort Lauderdale
Research Site, Montpellier
Research Site, Giessen
Research Site, Göttingen
Research Site, Nashville
Research Site, Bologna
Research Site, Seville
Research Site, Seville
Research Site, Columbus
Research Site, Dortmund
Research Site, Lünen
Research Site, Bochum
Research Site, Essen
Research Site, Valencia
Research Site, Royal Oak
Research Site, Troy
Research Site, Münster
Research Site, Osnabrück
Research Site, Angers
Research Site, Bonn
Research Site, Nancy
Research Site, Frankfurt am Main
Research Site, Clermont-Ferrand
Research Site, Frankfurt
Research Site, Alexandroupoli
Research Site, Mannheim
Research Site, Heidelberg
Research Site, Lyon
Research Site, Stuttgart
Research Site, Tübingen
Research Site, Tulsa
Research Site, Paris
Research Site, Paris
Research Site, Konstanz
Research Site, Austin
Research Site, Austin
Research Site, München
Research Site, Beersheba
Research Site, Augsburg
Research Site, Ulm
Research Site, Erlangen
Research Site, Jerusalem
Research Site, Suresnes
Research Site, Bad Neustadt an der Saale
Research Site, Arkhangelsk
Research Site, Novosibirsk
Research Site, Haifa
Research Site, Petah Tikva
Research Site, Tel Aviv
Research Site, Ashdod
Research Site, Jerusalem
Research Site, Calgary
Research Site, Edmonton
Research Site, New Westminster
Research Site, Vancouver
Research Site, Hamilton
Research Site, London
Research Site, Montreal
Research Site, Montreal
Research Site, Québec
Research Site, Brno
Research Site, Ostrava
Research Site, Prague
Research Site, Copenhagen
Research Site, Helsinki
Research Site, Turku
Research Site, Bourg-en-Bresse
Research Site, Perugia
Research Site, Roma
Research Site, Roma
Research Site, Riga
Research Site, Vilnius
Research Site, Amsterdam
Research Site, Amsterdam
Research Site, Enschede
Research Site, Leiden
Research Site, Zwolle
Research Site, Krakow
Research Site, Krakow
Research Site, Lublin
Research Site, Wejherowo
Research Site, Coimbra
Research Site, Vila Nova de Gaia
Research Site, Albacete
Research Site, Barcelona
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Lund
Research Site, Uppsala
Research Site, Cambridge
Research Site, Harrow
Research Site, Leeds
Research Site, Leicester
Research Site, London
Research Site, Newcastle upon Tyne
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY